Physician profile
Meaghan E Mollard
NPI 1295115806
$7,877.62
in general payments reported to CMS, 2019-2025
18 companies · $2,722 in 2025
The $2,722 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $751 · 2022: $1,047 · 2023: $1,416 · 2024: $1,942 · 2025: $2,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,231 · Travel and Lodging: $847 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,231.37 |
| Travel and Lodging | $847.33 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $5,527.83 | 2021-2025 | Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $688.80 | 2022-2025 | Versacross Access Solution, General - Therapies, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $278.11 | 2022-2024 | Farxiga |
| Abbott Laboratories | $221.32 | 2021-2025 | Navitor, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $202.77 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $169.36 | 2022-2024 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $148.77 | 2022 | |
| Pfizer INC. | $121.93 | 2022-2023 | |
| Acacia Pharma INC | $120.08 | 2022 | |
| Abiomed | $108.63 | 2022-2025 | Impella |
| Cvrx, INC. | $93.12 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $54.63 | 2021 | |
| Amgen INC. | $46.43 | 2021-2023 | Repatha |
| Cardiva Medical, INC. | $26.33 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Esperion Therapeutics, INC. | $22.50 | 2025 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.45 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.59 | 2023 | Inpefa |
| B. Braun Interventional Systems INC. | $12.97 | 2023 | No Marketed Product Name |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Mollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.